Ramdev Released Research Paper On Coronil

New Delhi : Yoga Guru Ramdev, the founder of Patanjali, released the first scientific research paper on the evidence-based medicine for COVID-19 by his organization. Union Health Minister, Dr Harsh Vardhan, and Union Minister Nitin Gadkari were also present at the event.

The medicine for which the data has been released is named Coronil. In June last year, Patanjali claimed that its Ayurvedic medicine can cure coronavirus infection. Following some controversy on the claims, Patanjali’s Coronil Kit was licensed as an ‘immunity booster’.

Swami Ramdev, at the event, said, that people believe that research work can only be conducted in the West. Especially when it comes to Ayurveda, people look at research work with suspicion. He also said that Coronil has benefited lakhs of people during the pandemic.

In June 2020, Patanjali Ayurved had launched ‘Coronil and Swasari’, which the company claimed was the first Ayurvedic cure for COVID-19, the respiratory disease caused by the novel coronavirus or SARS-CoV-2 virus. Launching a kit of three Ayurvedic medicines at Patanjali Yogpeeth in Haridwar, Uttarakhand, Yoga guru Ramdev had said they are proud to announce that the first Ayurvedic, clinically controlled trial based evidence and research-based medicine has been prepared by the combined efforts of Patanjali Research Centre and NIMS.

Ramdev had also said that the medicine could provide ‘100 per cent recovery rate within 3-7 days’.

  • Related Posts

    • Pharma
    • July 24, 2025
    • 158 views
    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

    • Pharma
    • July 22, 2025
    • 246 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra